Galapagos, a Belgium-based drugmaker, has selected the former head of a once-buzzy neuroscience startup

比利时制药商Galapagos已选中一家曾经备受关注的神经科学初创公司的前负责人。

to lead a spinout company

领导一家分拆公司

that will lean on deals to build its slate of research programs.

这将依靠交易来构建其研究计划的名单。

On Monday, Galapagos’ board of directors appointed Henry Gosebruch as CEO of the yet-to-be-officially-named spinout. The new company, which is

周一，加拉帕戈斯董事会任命亨利·戈塞布鲁赫为尚未正式命名的分拆公司的首席执行官。这家新公司，正处于

part of a larger restructuring effort

更大规模重组努力的一部分

announced early last year, will come equipped with 2.45 billion euros — or roughly $2.5 billion — of Galapagos’ cash. It plans to put at least some of that money into “strategic” transactions to achieve its ultimate goal of creating a

去年年初宣布的计划，将配备 24.5 亿欧元——约合 25 亿美元——的加拉帕戈斯现金。它计划将其中至少一部分资金投入到“战略性”交易中，以实现其创造一个

pipeline of “innovative medicines”

“创新药物”的管道

targeting cancer, viruses and the immune system.

针对癌症、病毒和免疫系统。

Previously a top dealmaker at J.P. Morgan and AbbVie, Gosebruch most recently served as CEO of Neumora Therapeutics, a

此前，戈塞布鲁赫曾是摩根大通和艾伯维的顶级交易撮合者，最近他还担任过纽莫拉治疗公司的首席执行官，这是一家

richly funded

资金充裕的

biotechnology firm aiming to create new treatments for psychiatric conditions and neuron-destroying diseases. He

生物技术公司，旨在为精神疾病和神经破坏性疾病创造新的治疗方法。他

left the biotech in February

于二月离开了生物技术公司

, a month after its most prized asset, an experimental drug for depression,

，一个月前其最宝贵的资产，一种治疗抑郁症的实验性药物，

suffered a major failure

遭受了重大故障

in clinical testing.

在临床测试中。

Neumora’s stock price has now

Neumora的股价现在

declined 96%

拒绝 96%

from when the firm went public in 2023.

自公司于 2023 年上市以来。

Galapagos shares, meanwhile, are down about 90% from five years ago, when the company was

同时，Galapagos的股价较五年前已下跌了约90%，当时该公司

fresh off a transformational agreement

刚刚达成一项转型协议

with Gilead Sciences. Galapagos has since hit a series of research setbacks that led it to

与吉利德科学公司合作后，Galapagos 遭遇了一系列研究挫折，导致它

lay off hundreds of employees

裁员数百名员工

and chart a new course

并绘制新的航线

focused on cellular medicines

专注于细胞药物

.

。

Once Galapagos fully separates from the spinout, it will continue to work on cell therapies for solid tumors and blood cancers. Its most advanced medicine is in mid-stage testing for several hard-to-treat kinds of lymphoma.

一旦 Galapagos 完全从分拆中脱离，它将继续致力于实体瘤和血癌的细胞疗法。其最先进的药物正在对几种难治性淋巴瘤进行中期测试。

The legacy organization will need to find a new leader, though, as CEO Paul Stoffels intends to retire from the position in the next 12 months. That announcement, also made Monday, said the Galapagos board will look for a successor who can lead the company “into its next phase of growth.” Stoffels came to Galapagos three years ago from Johnson & Johnson, where he spent nearly two decades helping shape the pharmaceutical giant’s research before retiring as its top scientist..

这家老牌机构需要寻找一位新的领导人，因为首席执行官保罗·斯托弗斯打算在未来12个月内退休。这项宣布同样在周一发布，称加拉帕戈斯董事会将寻找能够带领公司“进入下一个增长阶段”的继任者。斯托弗斯三年前从强生公司来到加拉帕戈斯，在强生工作了近二十年，帮助塑造了这家制药巨头的研发方向，后以首席科学家身份退休。

Stoffels isn’t fully stepping back from Galapagos, however, as he plans to stick around as the board’s non-executive chair — a role that would allow him to “continue to provide strategic guidance and support.” His reappointment will be determined at the company’s annual general meeting in 2026.

然而，斯托费尔斯并没有完全退出加拉帕戈斯公司，他计划继续担任董事会的非执行主席——这一角色将使他能够“继续提供战略指导和支持”。他的重新任命将在2026年公司的年度股东大会上决定。

In mid-February, Faisal Khurshid, an analyst at the investment bank Leerink Partners, wrote in a note to clients that the most important near-term event for Galapagos’ stock price could be the structure and leadership choices made for the spinout.

2月中旬，投资银行Leerink Partners的分析师费萨尔·库尔希德在给客户的一份报告中写道，对Galapagos股价而言，最重要的短期事件可能是分拆公司的结构和领导层选择。

While the spinout’s cash position and fixation on business development presents an “intriguing” opportunity, Khurshid proposed that investors “may need to see it to believe it.”

虽然该分拆公司的现金状况和对业务发展的专注提供了一个“引人入胜”的机会，但库尔希德建议投资者“可能需要亲眼看到才会相信”。

“Henry is the right leader to take on the CEO role for SpinCo as he leverages his extensive experience and the strong balance sheet to build an exciting pipeline,” Andrew Dickinson, Gilead’s chief financial officer and a non-executive, non-independent member of Galapagos’ board, said in a statement..

“亨利是担任SpinCo首席执行官的合适领导人，他将利用其丰富的经验和强大的资产负债表来建立令人兴奋的研发渠道，”吉利德首席财务官、Galapagos董事会非执行、非独立董事安德鲁·迪金森在一份声明中表示。

“Having worked closely with Henry on successful M&A in the past, I am delighted to welcome him to Galapagos,” added Jérôme Contamine, the lead non-executive board director.

“过去我曾与亨利密切合作，成功完成了并购交易，因此我非常高兴欢迎他加入Galapagos，”首席非执行董事杰罗姆·康塔明补充道。

Galapagos ended last year with 3.3 billion euros in cash. Around 500 million euros of that total will remain with the legacy organization so it can operate to 2028, when the company hopes that lead cell therapy program will gain regulatory approval.

去年年底，Galapagos公司拥有33亿欧元的现金。其中大约5亿欧元将留在原来的组织中，以便其能够运营到2028年，届时该公司希望其主要的细胞治疗计划能够获得监管机构的批准。